{"id":1847,"date":"2026-06-24T15:15:00","date_gmt":"2026-06-24T15:15:00","guid":{"rendered":"https:\/\/cielcharlotte.com\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/"},"modified":"2026-06-24T15:15:00","modified_gmt":"2026-06-24T15:15:00","slug":"celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug","status":"publish","type":"post","link":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/","title":{"rendered":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG"},"content":{"rendered":"

Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM);company also appoints Chief Commercial OfficerDEL MAR, Calif., June 24, 2026 \/PRNewswire\/ —\u00a0CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's\u2026<\/p>\n

Read the full release \u2192<\/a><\/p>\n

News provided by PR Newswire.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM);company also appoints Chief Commercial OfficerDEL MAR, Calif., June 24, 2026 \/PRNewswire\/ —\u00a0CeleCor Therapeutics has submitted the final section of its New Drug Application for the company’s\u2026<\/p>\n","protected":false},"author":14,"featured_media":1849,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1847","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-art-community"],"yoast_head":"\nCELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG - Ciel Charlotte<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG - Ciel Charlotte\" \/>\n<meta property=\"og:description\" content=\"Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM);company also appoints Chief Commercial OfficerDEL MAR, Calif., June 24, 2026 \/PRNewswire\/ --\u00a0CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/\" \/>\n<meta property=\"og:site_name\" content=\"Ciel Charlotte\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-24T15:15:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"384\" \/>\n\t<meta property=\"og:image:height\" content=\"253\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ethan Parker\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ethan Parker\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/\"},\"author\":{\"name\":\"Ethan Parker\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"headline\":\"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG\",\"datePublished\":\"2026-06-24T15:15:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/\"},\"wordCount\":59,\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png\",\"articleSection\":[\"Art Community\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/\",\"name\":\"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG - Ciel Charlotte\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png\",\"datePublished\":\"2026-06-24T15:15:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#primaryimage\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png\",\"width\":1536,\"height\":1024,\"caption\":\"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#website\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/\",\"name\":\"Ciel Charlotte\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/#\\\/schema\\\/person\\\/4c5e38434c81d2ebb9c5787b29251450\",\"name\":\"Ethan Parker\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"contentUrl\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/ethan-parkar-96x96.jpeg\",\"caption\":\"Ethan Parker\"},\"description\":\"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.\",\"url\":\"https:\\\/\\\/development.brstdev.com\\\/cielcharlotte\\\/author\\\/ethan-parker\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG - Ciel Charlotte","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG - Ciel Charlotte","og_description":"Filing follows release of positive Phase 3 study results for zalunfiban (DisaggproTM);company also appoints Chief Commercial OfficerDEL MAR, Calif., June 24, 2026 \/PRNewswire\/ --\u00a0CeleCor Therapeutics has submitted the final section of its New Drug Application for the company's\u2026","og_url":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/","og_site_name":"Ciel Charlotte","article_published_time":"2026-06-24T15:15:00+00:00","og_image":[{"width":384,"height":253,"url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/default-image.jpg","type":"image\/jpeg"}],"author":"Ethan Parker","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ethan Parker"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#article","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/"},"author":{"name":"Ethan Parker","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"headline":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG","datePublished":"2026-06-24T15:15:00+00:00","mainEntityOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/"},"wordCount":59,"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png","articleSection":["Art Community"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/","url":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/","name":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG - Ciel Charlotte","isPartOf":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website"},"primaryImageOfPage":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#primaryimage"},"image":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#primaryimage"},"thumbnailUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png","datePublished":"2026-06-24T15:15:00+00:00","author":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450"},"breadcrumb":{"@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#primaryimage","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/06\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug-ai.png","width":1536,"height":1024,"caption":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG"},{"@type":"BreadcrumbList","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/celecor-completes-submission-of-fda-new-drug-application-for-investigational-heart-attack-drug\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/development.brstdev.com\/cielcharlotte\/"},{"@type":"ListItem","position":2,"name":"CELECOR COMPLETES SUBMISSION OF FDA NEW DRUG APPLICATION FOR INVESTIGATIONAL HEART-ATTACK DRUG"}]},{"@type":"WebSite","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#website","url":"https:\/\/development.brstdev.com\/cielcharlotte\/","name":"Ciel Charlotte","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/development.brstdev.com\/cielcharlotte\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/#\/schema\/person\/4c5e38434c81d2ebb9c5787b29251450","name":"Ethan Parker","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","url":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","contentUrl":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-content\/uploads\/2026\/09\/ethan-parkar-96x96.jpeg","caption":"Ethan Parker"},"description":"Ethan Parker covers stories about community life, personal well-being, local initiatives, lifestyle trends, and the people working to create stronger communities. His writing looks for the human element behind larger developments, focusing on practical ideas and meaningful stories. Ethan brings an approachable perspective to subjects involving everyday life, community participation, creativity, and social connection.","url":"https:\/\/development.brstdev.com\/cielcharlotte\/author\/ethan-parker\/"}]}},"_links":{"self":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/1847","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/comments?post=1847"}],"version-history":[{"count":0,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/posts\/1847\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media\/1849"}],"wp:attachment":[{"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/media?parent=1847"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/categories?post=1847"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/development.brstdev.com\/cielcharlotte\/wp-json\/wp\/v2\/tags?post=1847"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}